This HTML5 document contains 135 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n13http://dx.doi.org/10.1007/
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
n8https://scigraph.springernature.com/pub.10.1007/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q43965995
rdf:type
wikibase:Item
schema:description
bài báo khoa học article scientifique teaduslik artikkel научни чланак 2011年学术文章 vetenskaplig artikel artigo científico 2011 nî lūn-bûn scientific article published on 15 October 2011 artikel ilmiah naučni članak научная статья 2011年學術文章 artículu científicu espublizáu en 2011 videnskabelig artikel 2011年学术文章 vědecký článek 2011年學術文章 artykuł naukowy 2011年の論文 artikull shkencor scientific article published on 15 October 2011 مقالة علمية نشرت في 15 أكتوبر 2011 articol științific 2011年学术文章 2011年學術文章 vitskapeleg artikkel научни чланак מאמר מדעי tieteellinen artikkeli artigo científico article científic tudományos cikk article scientific ১৫ অক্টোবর ২০১১-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ სამეცნიერო სტატია наукова стаття, опублікована в жовтні 2011 мақолаи илмӣ scienca artikolo artículo científico publicado en 2011 บทความทางวิทยาศาสตร์ vedecký článok wissenschaftlicher Artikel 2011年學術文章 vitenskapelig artikkel 2011年學術文章 artikulong pang-agham 2011年学术文章 scientific article published on 15 October 2011 2011년 논문 articolo scientifico wetenschappelijk artikel 2011年学术文章 научна статия επιστημονικό άρθρο artigo científico 2011年学术文章 bilimsel makale
p:P577
wds:Q43965995-F92A8E32-6F12-4900-9748-5D745DB38174
wdt:P577
2011-10-15T00:00:00Z
p:P2888
wds:Q43965995-4D51333A-4F38-443E-B128-346FF12B3727
wdt:P2888
n8:s00280-011-1757-y
p:P2860
wds:Q43965995-95C8DEE6-0F6F-4840-AB53-EC99EAF0C588 wds:Q43965995-68FC9218-39FF-4DB6-9B1D-04259BC20BA3 wds:Q43965995-734F320E-F3E3-45AA-BA78-85D8C1642146 wds:Q43965995-42E4E862-17BE-4523-A09E-935749028455 wds:Q43965995-51F1A8FB-A43E-48B3-A6D3-29F8E22F58F2 wds:Q43965995-402A73D3-A7BA-4193-8FFA-691CAB65FD7C wds:Q43965995-1A2A8A74-F436-4313-8B3F-0CD86E71672D wds:Q43965995-1CF26AF6-F1F1-4279-B972-604CD62FB2D6 wds:Q43965995-11F64149-668B-47E1-A8B7-FE208FC1F364 wds:Q43965995-EE9F5DDE-6D17-4949-B270-4942A5A762AA wds:Q43965995-FC5BBD3B-8190-4046-8FFD-914FAEF7EFA8 wds:Q43965995-C4318EFA-6392-4ECB-AFFA-DDE325E86E65 wds:Q43965995-E08C1DF0-87AC-430D-8CE0-647EB9691DC5 wds:Q43965995-A716B275-FBCF-4232-8287-2F5B4F320B21 wds:Q43965995-B76CA6F7-AC3A-4DE6-BE06-5475561D9885 wds:Q43965995-B7E7356C-942A-40D0-8577-552AD8AECC5B wds:Q43965995-BC2CD318-EF15-4DBF-BFD2-3C03D7D90099 wds:Q43965995-8E4EE153-6E65-40AE-933E-FE38012EAEB9
wdt:P2860
wd:Q29620605 wd:Q29619975 wd:Q36692592 wd:Q34271566 wd:Q29547545 wd:Q27824812 wd:Q46735180 wd:Q37573359 wd:Q33521023 wd:Q53606326 wd:Q43843455 wd:Q34522758 wd:Q34533636 wd:Q27860881 wd:Q46232500 wd:Q24561953 wd:Q44026405 wd:Q27861059
p:P2093
wds:Q43965995-7831CB57-AE5F-4AF5-8B03-2D3DE751F776 wds:Q43965995-E1BCA1FA-55A8-4C56-A754-EAAA69F812FD wds:Q43965995-90DC18C6-A086-4652-8FCF-98F1F186671D
wdt:P2093
Lawrence Leichman Alan Swaisland Elizabeth S Lowe
rdfs:label
Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study. Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study.
skos:prefLabel
Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study. Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study.
schema:name
Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study. Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study.
p:P50
wds:Q43965995-32B1131D-C58F-4512-B946-AE7F7825465E wds:Q43965995-D5124DA8-4B97-49D7-BACD-ABE3D42A3EDE
wdt:P50
wd:Q55743787 wd:Q5230638
p:P1476
wds:Q43965995-FC392AF8-523A-4F8A-9E6C-F28064D5119D
wdt:P1476
Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study
p:P304
wds:Q43965995-86F01458-0647-479B-94C3-DCB8E09D7E98
wdt:P304
273-280
p:P31
wds:Q43965995-5F75E74C-EB8B-40F5-9FB9-07FA3FE09265
wdt:P31
wd:Q13442814
p:P698
wds:Q43965995-3B817EC6-4993-485A-A7B8-0F508E65B4CB
wdtn:P698
n10:22002543
wdt:P698
22002543
p:P1433
wds:Q43965995-283178D1-6BDC-478C-88D3-1FFD81058042
wdt:P1433
wd:Q326137
p:P433
wds:Q43965995-132E4337-A4F0-4611-BB8A-C7F07C076DA5
p:P478
wds:Q43965995-3072ACFC-5CB4-4CF4-AD90-A89EDB7C5D3E
wdt:P433
1
wdt:P478
69
p:P356
wds:Q43965995-5304319E-33F5-4B25-A359-4859793F7AC9
wdtn:P356
n13:S00280-011-1757-Y
wdt:P356
10.1007/S00280-011-1757-Y
p:P6179
wds:Q43965995-FD02FECF-19A3-4FBD-B6D9-89B2F0918616
wdt:P6179
1052570613